Published in Vaccine Weekly, June 29th, 2005
The study demonstrated that men treated with Uroxatral (alfuzosin HCl), a clinically uroselective alpha-1-blocker for the treatment of the signs and symptoms of enlarged prostate, or benign prostatic hyperplasia (BPH), reported sustained benefit over 2 years in reducing lower urinary tract symptoms (LUTS) and improving sexual function.
Further, a second analysis from the trial demonstrated the relationship between LUTS severity and sexual function and showed that improvement in men with LUTS taking Uroxatral corresponded to similar...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly